QSAR Modeling of Anti-HIV Activities of Alkenyldiarylmethanes Using Topological and Physicochemical Descriptors

References

• http://www.unaids.org/Unaids/EN/Resources/Publications
   Google Scholar
• Mehanna, S. A. (2003). Rationale of design of anti-HIV drugs. In Burger's Medicinal Chemistry and Drug Discovery, edited by D. J. Abraham, New York: John Wiley & Sons, pp. 458- 483.
   Google Scholar
• Havlir, D. V., and Richman, D. D. (1996). Viral dynamics of HIV: Implications for drug development and therapeutic strategies. Ann. Intern. Med., 124, 984–994.
   PubMed Web of Science ®Google Scholar
• Carpenter, C. C., Fischl, M. A., Hammer, S. M., Hirsch, M. S., Jacobsen, D. M., Katzenstein, D. A., Montaner, J. S., Richman, D. D., Saag, M. S., Schooley, R. T., Thompson, M. A., Vella, S., Yeni, P. G., and Volberding, P. A. (1998). Antiretroviral therapy for HIV infection in 1998: Updated recommendations of the International AIDS Society-USA Panel. J. Am. Med. Ass., 280,78-86.
   Google Scholar
• Garg, R., Gupta, S. P., Gao, H., Babu, M. S., Debnath, A. K., and Hansch, C. (1999). Comparative quantitative structure-activity relationship studies on anti-HIV drugs. Chem. Rev., 99, 3525- 3601.
   PubMed Web of Science ®Google Scholar
• Gupta, S. P., and Nagappa, A. N. (2003). Design and development of integrase inhibitors as Anti-HIV agents. Curr. Med. Chem., 10, 1843–1858.
   Google Scholar
• Alkhatib, G., Combadiere, C., Broder, C. C., Feng, Y., Kennedy, P. E., Murphy, P. M., and Berger, E. A. (1996). CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science, 272, 1955- 1958.
   PubMed Web of Science ®Google Scholar
• Pungpo, P., Hannongbua, S., and Wolschann, P. (2003). Hologram quantitative structure-activity relationships investigations of non-nucleoside reverse transcriptase inhibitors. Curr. Med. Chem., 10, 1661–1677.
   PubMed Web of Science ®Google Scholar
• Weekes, D., and Fogel, G. B. (2003). Evolutionary optimization, backpropagation, and data preparation issues in QSAR modeling of HIV inhibition by HEPT derivatives. Biosystems, 72, 149–158.
   PubMed Web of Science ®Google Scholar
• Douali, L., Villemin, D., and Cherqaoui, D. (2003). Comparative QSAR based on neural networks for the anti-HIV activity of HEPT derivatives. Curr. Pharm. Des., 9, 1817–1826.
   PubMed Web of Science ®Google Scholar
• Douali, L., Villemin, D., and Cherqaoui, D. (2003). Neural networks: Accurate nonlinear QSAR model for HEPT derivatives. J. Chem. Inf. Comput. Sci., 43, 1200–1207.
   PubMedGoogle Scholar
• Mager, P. P. (2003). Hybrid canonical-correlation neural-network approach applied to nonnucleoside HIV-1 reverse transcriptase inhibitors (HEPT derivatives). Curr. Med. Chem., 10, 1643–1659.
   PubMed Web of Science ®Google Scholar
• Song, M., Breneman, C. M., and Sukumar, N. (2004). Three-dimensional quantitative structure-activity relationship analyses of piperidine-based CCR5 receptor antagonists. Bioorg. Med. Chem., 12, 489–499.
   PubMed Web of Science ®Google Scholar
• Kuo, C. L., Assefa, H., Kamath, S., Brzozowski, Z., Slawinski, J., Saczewski, F., Buolamwini, J. K., and Neamati, N. (2004). Application of CoMFA and CoMSIA 3D-QSAR and docking studies in optimization of mercaptobenzenesulfonamides as HIV-1 integrase inhibitors. J. Med. Chem., 47, 385- 399.
   PubMed Web of Science ®Google Scholar
• Costi, R., Santo, R. D., Artico, M., Massa, S., Ragno, R., Loddo, R., La Colla, M., Tramontano, E., La Colla, P., and Pani, A. (2004). 2,6-Bis(3,4,5-trihydroxybenzylydene) derivatives of cyclohexanone. Novel potent HIV-1 integrase inhibitors that prevent HIV-1 multiplication in cell-based assays. Bioorg. Med. Chem., 12, 199–215.
   PubMed Web of Science ®Google Scholar
• Senese, C. L., and Hopfinger, A. J. (2003). A simple clustering technique to improve QSAR model selection and predictivity: Application to a receptor independent 4D-QSAR analysis of cyclic urea derived inhibitors of HIV-1 protease. J. Chem. Inf. Comput. Sci., 43, 2180–2193.
   PubMedGoogle Scholar
• Avram, S., Svab, I., Bologa, C., and Flonta, M. L. (2003). Correlation between the predicted and the observed biological activity of the symmetric and nonsymmetric cyclic urea derivatives used as HIV-1 protease inhibitors. A 3D-QSAR-CoMFA method for new antiviral drug design. J. Cell Mol. Med., 7, 287–296.
   PubMed Web of Science ®Google Scholar
• Gordon, R. K., Ginalski, K., Rudnicki, W. R., Rychlewski, L., Pankaskie, M. C., Bujnicki, J. M., and Chiang, P. K. (2003). Anti-HIV-1 activity of 3-deaza-adenosine analogs. Inhibition of S-adenosylhomocysteine hydrolase and nucleotide congeners. Eur. J. Biochem., 270, 3507–3517.
   PubMedGoogle Scholar
• Kurup, A., Mekapati, S. B., Garg, R., and Hansch, C. (2003). HIV-1 protease inhibitors: A comparative QSAR analysis. Curr. Med. Chem., 10, 1679–1688.
   PubMed Web of Science ®Google Scholar
• Senese, C. L., and Hopfinger, A. J. (2003). Receptor-independent 4D-QSAR analysis of a set of norstatine derived inhibitors of HIV-1 protease. J. Chem. Inf. Comput. Sci., 43, 1297–1307.
   PubMedGoogle Scholar
• Brzezinska, E. (2003). The QSAR analysis of tricyclic nonnucleoside inhibitors of HIV-1 reverse transcriptase. Acta Pol. Pharm., 60,3-13.
   Google Scholar
• Kiralj, R., and Ferreira, M. M. (2003). A priori molecular descriptors in QSAR: A case of HIV-1 protease inhibitors. I. The chemometric approach. J. Mol. Graph. Model., 21, 435–448.
   PubMed Web of Science ®Google Scholar
• Roy, K., and Leonard, J. T. (2004). QSAR modeling of HIV-1 reverse transcriptase inhibitor 2-amino-6-arylsulfonylbenzonitriles and congeners using molecular connectivity and E-state parameters. Bioorg. Med. Chem., 12, 745–754.
   PubMed Web of Science ®Google Scholar
• Leonard, J. T., and Roy K. (2004). Classical QSAR modeling of HIV-1 reverse transcriptase inhibitor 2-amino-6-arylsulfonylbenzonitriles and congeners. QSAR Comb. Sci., 23, 23–35.
   Google Scholar
• Xu, G., Kannan, A., Hartman, T. L., Wargo, H., Watson, K., Turpin, J. A., Buckheit, R. W. Jr., Johnson. A. A., Pommier, Y., and Cushman, M. (2002). Synthesis of substituted diarylmethylenepiperidines (DAMPs), a novel class of anti-HIV agents. Bioorg. Med. Chem., 10, 2807–2816.
   PubMed Web of Science ®Google Scholar
• Xu, G., Hartman, T. L., Wargo, H., Turpin, J. A., Buckheit, R. W., and Cushman, M. (2002). Synthesis of alkenyldiaryl-methane (ADAM) non-nucleoside HIV-1 reverse transcriptase inhibitors with non-identical aromatic rings. Bioorg. Med. Chem., 10, 283–290.
   PubMed Web of Science ®Google Scholar
• Xu, G., Micklatcher, M., Silvestri, M. A., Hartman, T. L., Burrier, J., Osterling, M. C., Wargo, H., Turpin, J. A., Buckheit, R. W. Jr., and Cushman, M. (2001). The biological effects of structural variation at the meta position of the aromatic rings and at the end of the alkenyl chain in the alkenyldiarylmethane series of non-nucleoside reverse transcriptase inhibitors. J. Med. Chem., 44, 4092–4113.
   PubMed Web of Science ®Google Scholar
• Xu, G., Loftus, T. L., Wargo, H., Turpin, J. A., Buckheit, R. W. Jr., and Cushman, M. (2001). Solid-phase synthesis of the alkenyldiarylmethane (ADAM) series of non-nucleoside HIV-1 reverse transcriptase inhibitors. J. Org. Chem., 66, 5958- 5964.
   PubMed Web of Science ®Google Scholar
• Casimiro-Garcia, A., Micklatcher, M., Turpin, J. A., Stup, T. L., Watson, K., Buckheit, R. W., and Cushman, M. (1999). Novel modifications in the alkenyldiarylmethane (ADAM) series of non-nucleoside reverse transcriptase inhibitors. J. Med. Chem., 42, 4861–4874.
   PubMed Web of Science ®Google Scholar
• Cushman, M., Casimiro-Garcia, A., Hejchman, E., Ruell, J. A., Huang, M., Schaeffer, C. A., Williamson, K., Rice, W. G., and Buckheit, R. W. Jr. (1998). New alkenyldiarylmethanes with enhanced potencies as anti-HIV agents, which act as nonnucleoside reverse transcriptase inhibitors. J. Med. Chem., 41, 2076–2089.
   PubMed Web of Science ®Google Scholar
• Cushman, M., Golebiewski, W. M., Graham, L., Turpin, J. A., Rice, W. G., Fliakas-Boltz, V., and Buckheit, R. W. Jr. (1996). Synthesis and biological evaluation of certain alkenyldiarylmethanes as anti-HIV-1 agents, which act as non-nucleoside reverse transcriptase inhibitors. J. Med. Chem., 39, 3217- 3227.
   PubMed Web of Science ®Google Scholar
• Chem Draw Ultra Version 5.0 and Chem 3D Pro Version 5.0are programs of Chambridgesoft Corporation, MA, US.
   Google Scholar
• Ghose, A. K., and Crippen, G. M. (1987). Atomic physico-chemical parameters for three dimensional-structure-directed quantitative structure-activity relationships. 2. Modeling dispersive and hydrophobic interactions. J. Chem. Inf. Comput. Sci., 27,21-35.
   Google Scholar
• Cerius2 Version 4.6 software by Accelrys, Inc., San Diego, US.
   Google Scholar
• Franke, R. (1984). Theoretical Drug Design Methods. pp. 184- 195, Amsterdam: Elsevier.
   Google Scholar
• Franke, R., and Gruska, A. (1995). Principal component and factor analysis. In Chemometric Methods in Molecular Design, edited by H. van de Waterbeemd, Weinheim, Germany: VCH, pp. 113–163.
   Google Scholar
• SPSS is statistical software of SPSS Inc., IL, US.
   Google Scholar
• The GW-BASIC programs RRR98, KRPRES1 and KRPRES2were developed by Kunal Roy (1998) and standardized on known data sets.
   Google Scholar
• Snedecor, G. W., and Cochran, W. G. (1967). Statistical Methods, New Delhi: Oxford & IBH Publishing Co. Pvt. Ltd., pp. 381–418.
   Google Scholar
• Wold, S., and Eriksson, L. (1995). Statistical validation of QSAR results. In Chemometric Methods in Molecular Design,edited by H., van de Waterbeemd, Weinheim: VCH. pp. 312- 317.
   Google Scholar
• Debnath, A. K. (2001) Quantitative structure-activity relationship (QSAR): A versatile tool in drug design. In Combinatorial Library Design and Evaluation, edited by A. K. Ghose, and V. N. Viswanadhan, New York: Marcel Dekker, Inc., pp. 73- 129.
   Google Scholar